Onconova to Present Rigosertib Clinical Data at the 14th International Symposium on Myelodysplastic Syndromes
NEWTOWN, Pa., May 01, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes, today announced one oral and one poster presentation at the 14th International Symposium on Myelodysplastic Syndromes taking place May 3-6, 2017 at the Palacios de Congresos de Valencia in Valencia, Spain. These presentations will be made by the Company's collaborators from the Mount Sinai School of Medicine and the Cleveland Clinic.
Date: May 4th through May 6th
Time: 8:00 am
Location: Poster Presentation Section
Presenter: Dr. Aziz Nazha - Cleveland Clinic, Cleveland, Ohio
A Validation of a Post-Hypomethylating Agent Failure (HMAF) Prognostic Model in Myelodysplastic Syndromes (MDS) Patients Treated with Rigosertib versus Best Supportive Care (BSC) in a Randomized Controlled Phase III trial
Date: Saturday May 6th
Time: 8:30 am-10 am
Location: Auditorium 1
Presenter: Dr. Shyamala Navada - Mount Sinai School of Medicine, NYC
Combination of Oral Rigosertib and Injectable Azacitidine In Patients with Myelodysplastic Syndromes (MDS)
Additional details and content from these presentations will be available on the Company's website on the day of the presentations.
About Onconova Therapeutics, Inc.
Onconova Therapeutics, Inc. is a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS). Rigosertib, Onconova's lead candidate, is a proprietary Phase 3 small molecule agent, which blocks cellular signaling by targeting RAS effector pathways. Using a proprietary chemistry platform, Onconova has created a pipeline of targeted anti-cancer agents designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. Onconova has three product candidates in clinical trials and several active pre-clinical programs. Advanced clinical trials with Onconova's lead compound, rigosertib, are aimed at unmet medical needs of patients with MDS. For more information, please visit http://www.onconova.com .
GENERAL CONTACT: http://www.onconova.com/contact/ INVESTOR RELATIONS CONTACT: Lisa Sher, MBS Value Partners on behalf of Onconova Therapeutics Lisa.Sher@mbsvalue.com / (212) 750-5800
Information om Globenewswire
Følg pressemeddelelser fra Globenewswire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Globenewswire
LeddarTech inc.19.12.2018 06:06 | Pressemeddelelse
LeddarTech and Cailabs Sign Collaboration Agreement on Combining LiDAR and Laser Beam Shaping Solutions for the Automotive Market
BIOPAC Systems, Inc.19.12.2018 01:35 | Pressemeddelelse
Industry-leaders join BIOPAC for T4 Human Physiology Conference Set for August 12-14, 2019
Keynote18.12.2018 15:36 | Pressemeddelelse
The North American Bitcoin Conference Stands Out as One of 2019’s Most Important Worldwide Crypto Events
Crown Bioscience18.12.2018 14:31 | Pressemeddelelse
Crown Bioscience Creates Center of Excellence for Bioinformatics, Big Data, and Biomarker Discovery Services
LeddarTech inc.18.12.2018 06:06 | Pressemeddelelse
LeddarTech Selects BlackBerry’s QNX Operating System for its Auto and Mobility LiDAR Platform
Align Technology, Inc.18.12.2018 02:31 | Pressemeddelelse
Align Technology Reaches 6 Millionth Invisalign® Patient Milestone With Tween Patient From China
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.Besøg vores nyhedsrum